Bifidobacterium infantis (DSM 33361)
- a promising probiotic strain
In scientific studies, Bifidobacterium infantis (DSM 33361) has been associated with the healthy development of the digestive system in babies born prematurely.
Chr. Hansen’s Bifidobacterium infantis (DSM 33361)The Bifidobacterium infantis (DSM 33361) probiotic strain was isolated from the intestine of a healthy baby. Bifidobacterium infantis (DSM 33361) is safe for consumption; it has been granted QPS1 (Qualified Presumption of Safety) status in Europe. Bifidobacterium infantis (DSM 33361) has been used as an ingredient in food and food supplements since the early 1990s.
Bifidobacterium infantis (DSM 33361) has been associated with health benefits for preterm babies
Bifidobacterium infantis (DSM 33361) has been investigated as part of a specific three-strain probiotic blend in two high-quality scientific studies that included more than 1,200 premature babies. The other two strains in the blend are Bifidobacterium, BB-12® and Streptococcus thermophilus, TH-4®.
The studies suggest that Bifidobacterium infantis (DSM 33361) may help address digestive system issues that can occur in babies born prematurely. Specifically, the Bifidobacterium infantis (DSM 33361) probiotic strain may help lower the number of premature babies having digestive system development issues by up to 50%.2,3
Read more about the Bifidobacterium infantis (DSM 33361) strain in preterm babies .
The formation of a baby’s gut microbiome may be supported by a Bifidobacterium infantis strainHuman breast milk contains sugar molecules called human milk oligosaccharides (HMOs).4 These sugar molecules are important for the digestive health of babies because bifidobacteria (beneficial bacteria) use them to grow and increase in number in the gut. To be able to use the molecules, the gut bacteria must first break them down into useable parts. Unfortunately, the majority of bacteria in a baby’s gut are not able to use the molecules because they lack the enzymes needed to break them down. However, Bifidobacterium infantis bacterial strains do have these necessary enzymes. This suggests that a combination of HMOs and a Bifidobacterium infantis strain may help increase the number of beneficial bifidobacteria in a baby’s gut microbiome, which may have long term benefits for the baby’s health.5,6
The Bifidobacterium infantis (DSM 33361) probiotic strain in combination with other strains that are well-documented in babies, such as Bifidobacterium, BB-12® or Lactobacillus rhamnosus, LGG®, may help support the healthy development of babies.
Consult a health care professional to find out more about supporting the health of premature babies.
Read more about the importance of bifidobacteria for the development of a healthy gut microbiome .
BB-12®, LGG® and TH-4® are registered trademarks of Chr. Hansen A/S
The article is provided for informational purposes regarding probiotics and is not meant to suggest that any substance referenced in the article is intended to diagnose, cure, mitigate, treat, or prevent any disease.
At Chr. Hansen, our strains are backed by science. All of our probiotic strains are supported by clinical documentation. Learn more about the beneficial effects our strains have on different health areas.
References Open Close
- European Food Safety Authority (EFSA). EFSA journal 2012; 10(12):3020
- Jacobs SE, et al. Pediatrics. 2013;132(6):1055-62. (PubMed)
- Bin-Nun A, et al. J Pediatr. 2005;147(2):192-6. (PubMed)
- Kunz C, et al.Annu Rev Nutr. 2000;20:699–722. (PubMed)
- LoCascio, R.G.; Desai, P.; Sela, D.A.; Weimer, B.; Mills, D.A. Appl. Environ. Microbiol. 2010, 76, 7373–7381
- Walker WA. Pediatr Res. 2017;82(3):387-95. (PubMed)